Omni Nutraceuticals Launches National TV and Print Campaign for Inholtra Natural Pain Relief Formula With NFL Spokesman Joe Theismann.

Business Editors &Health/Medical Writers

LOS ANGELES--(BUSINESS WIRE)--Feb. 4, 2000

Omni Nutraceuticals Inc. (&uot;Omni&uot;) (Nasdaq:OMNT) today announced the launch of a $2 million television and print advertising campaign for the first quarter of 2000 featuring NFL veteran quarterback Joe Theismann as the company's spokesman for Inholtra(R) Natural Pain Formula. Concurrently, the company will launch a media campaign to publicize Theismann and Inholtra(R).

Inholtra(R) is a patented all-natural formula that is a safe alternative to non-natural and glucosamine-only supplements for maintaining healthy joints and cartilage.

The Inholtra(R) television commercials are scheduled for the programs &uot;Wheel of Fortune,&uot; &uot;Judge Judy,&uot; &uot;Jeopardy,&uot; &uot;Inside Edition,&uot; &uot;Sally Jessy Raphael,&uot; &uot;The Price is Right,&uot; &uot;Hard Copy,&uot; &uot;Home Improvement,&uot; &uot;Donny &Marie&uot; and &uot;Regis and Kathy Lee,&uot; and will also air on CNN, ESPN, Fox News Channel, Fox Family Channel, A&, Court TV, Lifetime Network and Food Network, among others.

The company has placed print ads in Time magazine, Newsweek, U.S. News &World Report, Parade, People, Sports Illustrated, Let's Live, Natural Health, Car &Driver, This Old House, Arthritis Today and Prevention. During the first quarter of 2000, Omni Nutraceuticals will invest approximately $1 million in television and approximately $1 million in print advertising to promote Inholtra(R).

The company hopes that the campaign featuring Theismann and his mother will help increase sales of Inholtra(R), which is now sold in 13,000 mass market retail outlets and 4,000 health food stores nationwide.

&uot;The glucosamine category is a challenging one,&uot; said Omni Nutraceuticals CEO Louis Mancini. &uot;But we believe that Inholtra has the edge because it is not just another glucosamine-only supplement, but rather a unique, patented formula containing nine synergistic ingredients that work to attack the problems of arthritis, sports injuries and other joint-related conditions from several angles. We believe that Inholtra's patented formula is more effective than glucosamine alone.&uot;

Approximately 80 million Americans suffer from one form or another of joint pain due to loss of cartilage and/or lubricating fluid, which strikes more people in the United States than any other country and consumes nearly $70 billion per year in health-care costs, lost wages and 18% of all physician visits.

Only Inholtra's patented formula combines nine synergistic ingredients, two forms of glucosamine, omega-3 and omega-6 essential fatty acids (EPA, DHA and GLA), antioxidants (vitamins C &E), potassium-bound glucosamine (for low-sodium dietary needs) and utilizes Softgel(TM) capsules, which are easy to digest and provide optimum absorption.

The Inholtra(R) formula is 100% natural, has been found to be free of side-effects and requires no prescription. The Inholtra(R) product line includes Inholtra(R) Natural Pain Formula, Inholtra SulfaMax(TM) Natural MSM Formula, and InholtraNOW(TM) Natural Pain Cream, and is available at GNC and other health food stores.

Omni Nutraceuticals Inc. is a leading formulator and supplier of natural health, herbal and nutritional supplement products for consumers. Its product lines include popular brand-name market leaders such as Diet System Six(TM), Nature's Secret(R), Harmony Formulas(R), Applied Nutrition(TM), Dr. Linus Pauling Vitamins(R), Lifestyle Control Formulas(TM), Inholtra(R), 151 Bar(TM) and Cholestaid(TM).

The company's products are sold in specialty natural health, nutrition, food and mass retail stores worldwide.

Statements made in this news release, including those relating to increased sales of Inholtra(R), scheduled television commercials and print exposure, are forward looking and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties, which may cause results to differ materially from those set forth in these statements. Other factors identified in Omni's filings with the Securities and Exchange Commission could also affect the forward-looking statements contained in this news release.